Chirhostim Generic Name & Formulations
Human secretin 16mcg, 40mcg; per vial; lyophilized pwd for IV injection after reconstitution.
For the stimulation of pancreatic secretions, including bicarbonate to aid in the diagnosis of pancreatic exocrine dysfunction, and to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). For the stimulation of gastrin secretin to aid in the diagnosis of gastrinoma.
Chirhostim Dosage and Administration
See full labeling. Discontinue interacting drugs (eg, anticholinergics, H2-receptor antagonists, or PPIs) prior to testing accordingly; see Interactions. Administer as IV inj over 1min. Exocrine pancreas dysfunction (fast for at least 12–15hrs prior to testing): 0.2mcg/kg. ERCP: 0.2mcg/kg. Gastrinoma (fast for at least 12hrs prior to testing): 0.4mcg/kg.
Chirhostim Boxed Warnings
Stimulation testing should only be performed by physicians with sufficient expertise. Undergone vagotomy, inflammatory bowel disease: may be hyporesponsive to stimulation. Alcoholic or other liver disease: may be hyperresponsive to stimulation. Pregnancy. Nursing mothers.
Possible hyporesponse to stimulation testing with concomitant anticholinergics; discontinue at least 5 half-lives prior to testing. Possible hyperresponse with concomitant H2-receptor antagonists; discontinue at least 2 days prior to testing. Concomitant PPIs may cause hyperresponse to stimulation: refer to specific labeling prior to testing.
Chirhostim Adverse Reactions
Nausea, vomiting, flushing, upset stomach.
Chirhostim Clinical Trials
Chirhostim Patient Counseling